|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
RED CELLS
From the Cincinnati Comprehensive Sickle Cell Center
and the Divisions of Pediatric and Medical Hematology/Oncology,
University of Cincinnati College of Medicine, Cincinnati, OH.
Sickling-induced cation fluxes contribute to cellular dehydration
of sickle red blood cells (SS RBCs), which in turn potentiates sickling. This study examined the inhibition by dipyridamole of the
sickling-induced fluxes of Na+, K+, and
Ca++ in vitro. At 2% hematocrit, 10 µM dipyridamole
inhibited 65% of the increase in net fluxes of Na+ and
K+ produced by deoxygenation of SS RBCs. Sickle-induced
Ca++ influx, assayed as 45Ca++
uptake in quin-2-loaded SS RBCs, was also partially blocked by dipyridamole, with a dose response similar to that of Na+
and K+ fluxes. In addition, dipyridamole inhibited the
Ca++-activated K+ flux (via the Gardos pathway)
in SS RBCs, measured as net K+ efflux in oxygenated cells
exposed to ionophore A23187 in the presence of external
Ca++, but this effect resulted from reduced anion
conductance, rather than from a direct effect on the K+
channel. The degree of inhibition of sickling-induced fluxes was
dependent on hematocrit, and up to 30% of dipyridamole was bound to
RBC membranes at 2% hematocrit. RBC membrane content of dipyridamole
was measured fluorometrically and correlated with sickling-induced flux
inhibition at various concentrations of drug. Membrane drug content in
patients taking dipyridamole for other clinical indications was similar
to that producing inhibition of sickling-induced fluxes in vitro. These
data suggest that dipyridamole might inhibit sickling-induced fluxes of
Na+, K+, and Ca++ in vivo and
therefore have potential as a pharmacological agent to reduce SS RBC dehydration.
(Blood. 2001;97:3976-3983) Polymerization of sickle hemoglobin
(HbS) upon deoxygenation produces dramatic changes in red cell
shape,1 and the resultant membrane distortion is
associated with an increase in permeability to Na+,
K+, Ca++, and Mg++.2-6
This sickling-induced change in permeability leads to cation loss and
dehydration by 3 potential mechanisms: (1) imbalance between
K+ loss and Na+ gain via the sickling-induced
pathway per se in the presence of external
Ca++,3,4 (2) unbalanced compensation by the
Na+ pump (3 Naout for 2 Kin) in
response to elevated cellular Na+,9 (3)
increased Ca++ influx, with transient elevation of cellular
Ca++ leading to activation of the
Ca++-dependent K+ channel.4,8,10
In turn, the resultant cellular dehydration potentiates sickling
because of the high dependence of the rate of polymerization on HbS
concentration,12 producing a vicious cycle of sickling The physiological characteristics of the sickling-induced cation fluxes
are most consistent with a passive diffusional pathway. These fluxes
are linearly dependent on the concentration of the transported ion and
are responsive to changes in membrane potential.2 Sickling-induced fluxes of Na+ and K+ are
independent of Cl Several inhibitors have been shown to block sickling-induced cation
fluxes. DIDS (4,4'-di-isothiocyanato-2,2'-disulfostilbene) and related
stilbene disulfonates inhibit the sickling-induced movements of
Na+, K+, and Ca++.6,14
We demonstrated that this inhibitory effect could be dissociated from
inhibition of anion transport, indicating a site of action distinct
from the normal anion exchange protein.14 Nifedipine and
other Ca++ channel blockers inhibit sickling-induced
dehydration of sickle (SS) RBCs,15 and we have found that
sickling-induced Na+ and K+ fluxes were blocked
by nifedipine.16 In addition, we found14,17 that sickling-induced Na+ and K+ fluxes were
inhibited by dipyridamole, a drug that blocks anion exchange18 but also exhibits broad pharmacological activity on nucleotide transport19 and other biochemical
processes.20 Because of the therapeutic potential of
dipyridamole for inhibiting sickling-induced cation fluxes and
subsequent cellular dehydration in sickle cell patients, we undertook
further study of dipyridamole inhibition of sickling-induced
Na+, K+, and Ca++ fluxes and its
relationship to drug binding to the RBC membrane. Preliminary reports
of this work have appeared previously.16,17
Blood samples
Hematocrits were measured on oxygenated samples in microhematocrit
tubes, centrifuged 5 minutes at 13 000g. When stored
overnight, cells were suspended in Hepes
(N-2-hydroxyethyl-piperazine-N'-2-ethane sulfonic
acid)-buffered solution containing 15 mM NaCl and 125 mM KCl. In some
experiments, cells were fractionated according to density by
centrifugation on discontinuous gradients of Percoll (Pharmacia, Upsala, Sweden), as described previously.3
Whole blood was applied directly to gradients, which were
centrifuged at 3000g in a Beckman GPR centrifuge (Beckman
Coulter, Fullerton, CA) at 4°C. Cells were washed 3 times in
Hepes-buffered saline (HBS) to remove gradient material, and the
proportion of cells in the resultant fractions was calculated from
hemoglobin measurements.
Incubation media and drugs
Monovalent cation fluxes Net Na+ and K+ fluxes were measured as described previously.2,3,14 Briefly, cells were washed and resuspended at 2% hematocrit in HBS containing ouabain (0.1 mM), and paired suspensions were subjected to oxygenated or deoxygenated conditions. An initial triplicate sample was taken at 15 minutes and a final sample at 135 minutes, and hemolysate cation concentration was measured by flame emission (PerkinElmer, Norwalk, CT, model 370 atomic absorption spectrophotometer). The hemoglobin concentration of each hemolysate, assayed optically at 540 nm on a Beckman Instruments DU spectrophotometer, was used to calculate cation content (millimole per kilogram of hemoglobin). Net fluxes were calculated as the change in cellular cation content with time; the difference between fluxes in deoxygenated and oxygenated cells constitutes the sickling-induced flux.In one series of experiments, Rb+ influx was measured in cells incubated in HBS in which 5 mM RbCl replaced KCl. Cellular Rb+ content was measure by flame emission, as for Na+ and K+, on samples taken at 5 and 65 minutes. Rb+ influx was calculated as the change in Rb content over the incubation time, and the difference in Rb+ influx without and with 0.1 mM ouabain defined the Na+/K+ pump rate. For measurement of KCl cotransport, cells were incubated for 1 hour at
37° at pH 6.8 in HBS or equivalent solutions in which NO Calcium influx Ca++ influx was measured as 45Ca++ uptake into cells loaded with quin-2 in a modification of the procedure of Rhoda et al.6 This approach allows the estimation of unidirectional influx rates for 45Ca++ because efflux via Ca++-pump activity is inhibited, as accumulated intracellular Ca++ is chelated by quin-2 rather than being extruded by the pump.22 Cells of intermediate density (1.083 < < 1.094) were washed 3 times in buffer C and
incubated 45 minutes at 37°C at 10% hematocrit to ensure repletion
of cellular energy stores.22 After washing 3 times in
buffer B, cells were incubated 1 hour at 37°C at 10% hematocrit with
40 µM quin-2 acetoxymethylester (Molecular Probes) added as a 10 mM-stock in DMSO. Cellular concentration of quin-2 under these
conditions was estimated at 200 µmol per liter of cells by measurement of quin-2 fluorescence at 500 nm
(excitation at 335 nm) on hemolysates of loaded
cells.6
Quin-2-loaded cells were washed 3 times in buffer A and resuspended at 10% hematocrit. We transferred 2-mL aliquots to 20-mL glass tubes and added 0.1 M CaCl2 to give a final concentration of 1.0 mM. Dipyridamole was added as a 10-mM stock solution in DMSO to selected tubes, and DMSO was added to controls. Tubes were warmed to 37°C for 10 minutes in a heating block with constant stirring via magnetic fleas and fitted with stoppers with gas inlet ports. Deoxygenation was accomplished by flushing humidified N2 through the tubes; oxygenated samples were capped. The hemoglobin concentrations of each suspension were unaffected by N2 exposure, indicating adequate gas hydration. After 5 to 20 minutes of N2 exposure as indicated for individual experiments, 40 µCi 45CaCl2 (New England Nuclear, Boston, MA) was added, and single 100-µL samples were taken at 5-minute intervals for 45 minutes. Samples were taken into 1.5-mL Eppendorf tubes containing 1 mL of buffer A, layered over 200 µL dibutyl phthalate. Centrifugation at 13 000g for 1 minute pelleted the cells beneath the oil, and the tube was washed twice with buffer A without disturbing the cell pellet. After removal of the oil, the cells were lysed with 750 µL water. Hemolysates were precipitated with 250 µL of 20% trichloroacetic acid (TCA) and centrifuged, and aliquots of clear supernant were taken for counting. Samples of suspension were also precipitated with TCA and counted for measurement of 45Ca++-specific activity. Ca++ uptake was calculated as micromoles per liter of cells and was plotted versus time; slopes of these lines yielded flux rates. Measurement of dipyridamole in solution and RBC membranes Dipyridamole was measured in HBS by fluorescence at 480 nm with excitation at 293 nm in a fluorescence spectrometer (Model Fluoro IV) (Gilford Instruments, Oberlin, OH). After exposure to dipyridamole in vitro or in vivo, cells were washed 3 times in HBS at 4°C and then lysed in 10 volumes of 5 mM NaH2PO4, pH 8 (5P8), and the ghosts washed until white. Suspensions of ghost protein were adjusted to 1.0 mg/mL, assay by the method of Lowry.23 Ghosts were diluted to 100 µg/mL in HBS and assayed by excitation scan by fluorescence spectroscopy, with emission monitoring at 480 nm, as shown in Figure 1 for control ghosts (panel A) and ghosts exposed to dipyridamole (panel B). At the 293-nm excitation peak, the difference in the fluorescence reading between dipyridamole membranes and control membranes was measured. In all such assays, the same instrument settings were used consistently.
Inhibition of sickling-induced Na+ and K+ fluxes in SS RBCs by dipyridamole Figure 2 illustrates the effect of various concentrations of dipyridamole on sickling-induced Na+ and K+ fluxes measured at 2% hematocrit in HBS. It should be noted that the nominal drug concentrations in Figure 2 do not correspond to "free" concentrations because of extensive binding of this lipophilic drug to RBCs, as is explored in detail below. Inhibition of sickling-induced fluxes was not a result of inhibition of sickling by dipyridamole. In a separate series of 3 experiments, control samples fixed in 1% glutaraldehyde exhibited 86% ± 3% sickle forms, and those exposed to dipyridamole showed 85% ± 2% sickling. There were no qualitative differences between control and drug-treated cells in the shape changes induced by deoxygenation (not shown).
The media in these experiments contained no external Ca++, so that K+ efflux from deoxygenated SS RBCs under these conditions was mediated predominantly by the sickling-induced pathway, with no measurable fluxes via the Ca++-activated K+ channel.3 However, because there is evidence that this channel is activated by Ca++ influx mediated by the sickling-induced pathway in vivo,10 we examined the effect of dipyrimadole on Ca++ fluxes in deoxygenated SS RBCs. Inhibition of sickling-induced Ca++ influx by dipyridamole A typical experiment illustrating the effect of dipyridamole on 45Ca++ influx in quin-2-loaded SS RBCs is shown in Figure 3. Ca++ uptake in oxygenated cells was unaffected by drug; in 7 measurements, Ca++ influx was 0.24 ± 0.10 µmol per liter of cells per minute in control oxygenated cells and 0.23 ± 0.10 in oxygenated cells exposed to 100 µM dipyridamole. The increase in Ca++ uptake induced by deoxygenation is apparent in Figure 3 and is reduced in the presence of 100 µM dipyridamole. The results of 5 experiments of similar design are shown in Figure 4. Under these conditions, the sickling-induced Ca++ influx, calculated by subtracting the flux in oxygenated cells from that in deoxygenated cells, was inhibited 62% ± 12% by 100 µM dipyridamole. These data also illustrate that DIDS inhibited sickling-induced Ca++ influx by 33% ± 6%, confirming the findings of Rhoda et al.6 The combination of DIDS and dipyridamole did not produce significant additive inhibition, consistent with the 2 drugs acting on the same pathway.
Figure 5 shows the dose response to
dipyridamole of sickling-induced Ca++ influx, compared with
inhibition of sickling-induced Na+ influx and
K+ efflux measured under the same experimental conditions
as the 45Ca++ uptake measurements. Under these
conditions, sickling-induced Ca++ influx was inhibited in
parallel with Na+ influx, although the dose-response curve
was somewhat different than in previous Na+ influx
experiments (Figure 2). Differences in hematocrit (10% in Figure 5
versus 2% in Figure 2) and different conditions of deoxygenation may
account for this variation. Nevertheless, the similarity in the
dose-response curve for inhibition of sickling-induced Ca++
and Na+ influx, as illustrated in Figure 5, is consistent
with mediation of the 2 fluxes by the same pathway.
Inhibition of the Ca++-activated K+ channel (Gardos pathway) by dipyridamole Under certain, but not all, experimental conditions, a portion of the K+ loss from deoxygenated SS RBCs appears to be mediated by transient activation of the Gardos pathway by Ca++ influx via the sickling-induced pathway.4,10,11 It is known that anion-transport inhibitors,23,25 including dipyridamole,18,21 block Ca++-activated K+ fluxes since the extremely rapid, electrogenic K+ movements via the Ca++-activated channel are limited by conductive anion permeability, mediated predominately by the anion exchanger.26 We compared the dipyridamole dose response of the Ca++-activated K+ flux and the sickling-induced Na+ influx by parallel measurements of the 2 fluxes in aliquots of the same cell suspension under similar conditions of hematocrit and drug exposure as shown in Figure 6. Ca++-activated K+ efflux was measured in SS RBCs incubated with ionophore A23187 in the presence of Ca++ at 2% hematocrit. Dose-dependent inhibition of the Ca++-dependent K+ efflux (Figure 6) occurred at higher concentrations of dipyridamole than are required for inhibition of the sickling-dependent Na+ influx measured under the same conditions.
To demonstrate that dipyridamole inhibition of
Ca++-activated K+ fluxes in RBCs under the
conditions of these experiments was a consequence of the drug's action
on anion permeability, we measured fluxes in media in which
I
Electroneutral cation transport pathways or pathways mediating
electrogenic cation movements, which are slow relative to
K+ channel fluxes, are not rate-limited by conductive anion
permeability and would not be expected to be affected by anion channel
blockade. The sickling-induced pathway falls into the latter category.
Indeed, we have demonstrated that inhibition by DIDS of the
sickling-induced movements of Na+ and K+ is not
abrogated by substitution of I Effect of dipyridamole on the Na+/K+ pump and KCl cotransport The effect of dipyridamole on the activity of the Na+/K+ pump was assessed by measuring ouabain-sensitive Rb+ uptake at 5 mM external Rb+ (see "Materials and methods") in the presence or absence of 10 µM drug at 2% hematocrit. Pump activities were the same in control and drug-treated cells (5.5 ± 1.6 mmol/kg Hb per hour versus 5.2 ± 2.0 mmol/kg Hb per hour, respectively; n = 4 SS subjects). There was no effect of dipyridamole on ouabain-insensitive Rb+ influx rate. KCl cotransport, activated by either acidic or hypotonic conditions, was not consistently or significantly altered by dipyridamole. Cl -dependent K+ efflux from SS RBCs incubated
at pH 6.8 in isotonic solutions was 10.3 ± 3.9 mmol/kg Hb
per hour in control cells versus 15.1 ± 3.0 mmol/kg Hb per
hour in drug-treated cells (n = 3 SS subjects; P > .30
by paired t test). Swelling activated KCl cotransport, measured at normal pH in hypotonic solutions of 220 mOsm,27 was 7.2 ± 3.1 mmol/kg Hb per hour in
control cells versus 5.1 ± 4.4 mmol/kg Hb per hour
with drug (n = 4 SS subjects, P > .26).
Dipyridamole binding to RBCs In pilot experiments, inhibition of sickling-induced Na+ influx at 10 µM dipyridamole was 64% ± 6% at 2% hematocrit, but only 43% ± 5% at 10% hematocrit.17 This suggests that substantial dipyridamole binding to RBCs occurs in vitro; this was examined in 2 ways.First, the removal of dipyridamole from media upon exposure to RBCs was
investigated by measurement of residual dipyridamole in solutions by
fluorescence, as described in "Materials and methods." Figure
8 illustrates the fluorescence values at
several different drug concentrations. For the preparation of a
standard curve (upper curve in Figure 8), cells were incubated without
dipyridamole for 30 minutes at 2% hematocrit in HBS and then
centrifuged. The supernatant was recovered and used to prepare
solutions of various concentrations of dipyridamole for fluorescence
assay, as depicted by circles in Figure 8. In parallel, the same
concentrations of drug were added to identical 2% suspensions of RBCs,
incubated, and then centrifuged; the fluorescence readings on these
supernatants are shown in the middle curve (squares) of Figure 8.
Fluorescence was reduced by 30% to 50% upon exposure to RBCs,
depending on the initial concentration of drug. Because the control
samples had been exposed to RBCs under similar conditions before the
addition of drug, reduction in fluorescence by quenching by small
amounts of extracellular hemoglobin can be eliminated as an
explanation. To examine the role of hemoglobin in dipyridamole binding
to intact RBCs, "red" ghosts containing 10% of normal hemoglobin
concentration were prepared by osmotic lysis and resealing and were
exposed to drug under similar conditions of hematocrit and drug
concentrations (triangles in Figure 8). Supernatants were then
recovered for fluorescence assay of dipyridamole. Ghost bound similar
amounts of drug as intact RBCs. These results indicate that at 2%
hematocrit, RBCs bind one third to one half of dipyridamole added in
vitro and that the majority of the drug is bound by to the RBC
membrane. This fact makes the interpretation of the dose response of
dipyridamole inhibition of sickling-induced cation fluxes difficult,
especially in comparison with pharmacological drug levels in patients
taking the drug chronically, where tissue distributions of drug may be different from acute exposure of cells to drug in vitro. To address this issue, we compared the membrane content of dipyridamole required for inhibition of sickling-induced fluxes in vitro with membrane drug
content achieved in vivo.
Measurement of dipyridamole content of RBC membranes and correlation with sickling-induced flux inhibition Sickle cells were incubated at 2% hematocrit in HBS at various concentrations of dipyridamole, and sickling-induced Na+ influx was measured. From cells remaining after the flux measurement, ghost membranes were prepared as in Figure 1 for measurement of dipyridamole fluorescence. Figure 9A shows a linear relationship between membrane fluorescence and the nominal dipyridamole concentration in the incubation medium, indicating that drug binding to or partitioning into the membrane does not saturate in this concentration range. Inhibition of sickling-induced Na+ influx, however, saturates at around 30 µM nominal concentration, as illustrated in Figure 9B for these experiments. In Figure 9C, the sickling-induced Na+ influx values have been plotted against the membrane fluorescence values for each concentration of dipyridamole tested. This allows a comparison of the membrane content of dipyridamole required for inhibition of the sickling-induced flux to that achieved in patients taking the drug therapeutically. These values are depicted in Figure 9C as arrows on the x-axis for 2 patients with sickle cell anemia and 2 patients with Hb A. Although there is variation in the membrane levels of dipyridamole (including one SS patient in whom 2 determinations were made), it is apparent that the membrane content of drug achieved by oral administration of dipyridamole corresponds to that producing significant inhibition of sickling-induced fluxes in vitro.
Dipyridamole has multiple pharmacological effects, which include
inhibiting anion transport,18 blocking cellular adenosine uptake,19 inhibiting phosphodiesterase,20 and
scavenging oxidant radicals.28 To that list of diverse
effects on membrane processes, we now add blockade of the increased
membrane permeability to Na+, K+, and
Ca++ induced by sickling. Morphological sickling was not
altered by the drug, so the inhibitory effect of dipyridamole does not
result from interference with polymerization of deoxygenated HbS.
Dipyridamole also blocks K+ efflux via the
Ca++-activated K+ channel, because of its
inhibition of anion movements.21 The persistence of
Ca++-activated K+ fluxes in
dipyridamole-treated cells incubated in I We and others have previously shown that another anion-transport
inhibitor, DIDS, blocks the sickling-induced cation
movements.6,14 However, several lines of evidence indicate
that DIDS blockade of these cation movements is not a consequence of
its inhibition of conductive anion permeability. First, DIDS inhibition
of the anion exchanger could be dissociated from that of the
sickling-induced pathway on the basis of differences in dose-response
relationships and irreversible binding at 4°C. Second, several other
anion-transport inhibitors (phloretin and sulfophenyl isothiocyanate)
did not affect sickling-induced fluxes. Finally, substitution of
I Although both the sickling-induced pathway and the
Ca++-activated K+ channel are
electrogenic,2 Na+ and K+ fluxes
mediated by the sickling-induced pathway are not dependent on anion
permeability for two reasons. First, under physiological conditions,
Na+ influx and K+ efflux via the pathway nearly
balance each other, so that little or no net anion flux is required to
maintain electroneutrality. However, activation of a
K+-selective channel produces a unidirectional cation
[K+] efflux that requires equivalent anion movement.
Second, the rate of the sickling-induced Na+ and
K+ flux is several orders of magnitude lower than
conductive anion movement, even in DIDS-treated cells.26
Thus, even under conditions in which Na and K fluxes via the
sickling-induced pathway were not balanced, conductive anion
permeability would not be rate limiting. In contrast, opening of the
Ca++-activated K+ channel produces a
K+ permeability higher than Cl Thus, it is unlikely that the capacity of dipyridamole to inhibit sickling-induced cation fluxes is related to the drug's effect on anion exchange. The differences in the dipyridamole dose-response curves of the sickling-induced cation flux and the Ca++-activated K+ flux (Figure 6) support this conclusion. Partial inhibition of the sickling-induced fluxes by dipyridamole and DIDS could reflect the involvement of multiple pathways of variable sensitivity to inhibitors. However, the physiological characteristics of the sickling-induced fluxes suggest a single, passive diffusion pathway2 that does not distinguish between monovalent and divalent metal cations but does appear to exclude organic cations of similar size.2 We have suggested that the pathway reflects the activity of a nonselective cation channel, activated by the membrane distortion associated with sickling. Many of the characteristics of sickling-induced cation fluxes, including inhibition by DIDS,29 are shared by the passive cation leaks induced by high shear stress in normal and sickle RBCs.30 Recently, we described single ion channels in membrane vesicles derived from the spectrin-depleted spicules of sickled RBCs. These ion channels were nonselective and were partially inhibited by DIDS as a result of reduction in open probability.31 Partial inhibition by DIDS and dipyridamole of sickling-induced cation fluxes in intact cells might result from similar effects on open probability of such a channel. Dipyridamole inhibition of the sickling-induced cation transport pathway in vivo could have important implications for volume regulation of SS RBCs. Imbalance between Na+ influx and K+ efflux via this pathway,3,4 magnified by the unbalanced stoichiometry of the Na/K pump,9 may produce gradual dehydration of SS RBCs in vivo. The sickling-induced pathway also mediates the influx of Ca++ responsible for transient activation of the Ca++-activated K+ channel, which can produce rapid dehydration.4,10,11 Even partial inhibition of sickling-induced Ca++-influx might prevent cellular ionized Ca++ from rising to the threshold of activation of the channel. Dipyridamole inhibition of K+ efflux via the Ca++-activated channel might also retard dehydration of SS RBCs in vivo, even though the effect is secondary to reduction in net anion conductance. Bennekou32 has presented a detailed theoretical analysis demonstrating that anion-transport inhibition has the potential to retard rapid net cation loss in RBCs, especially that mediated by transient activation of high cation conductance pathways such the K+ channel. This phenomenon was demonstrated in vitro years ago by Eaton and colleagues,24 who showed that Ca++-activated K+ efflux was inhibited by DIDS. Gardos and colleagues showed that dipyridamole inhibited K+ fluxes mediated by the Ca++-activated channel,21 although the mechanism of inhibition via anion channel blockade was not appreciated at that time. Recently, Bennekou and colleagues25 demonstrated blockade of Ca++-activated K+ efflux by a new anion-transport inhibitor, NS1652. This drug also inhibited K+ efflux in deoxygenated SS RBCs, although a direct effect of the drug on the sickling-induced pathway was not excluded. It should be re-emphasized that dipyridamole's inhibition of sickling-induced Na+, K+, and Ca++ fluxes is not a consequence of its effect on anion conductance, since these cation fluxes are not limited by anion movements. Nevertheless, the therapeutic potential of dipyridamole might be enhanced if Ca++-activated K+ channel activity was also inhibited in vivo by a pharmacologic reduction in anion conductance. In summary, dipyridamole might inhibit K loss from deoxygenated SS RBCs in vivo in 3 ways: (1) by inhibiting unbalanced Na+ and K+ movements mediated by the sickling-induced pathway; (2) by reducing sickling-induced Ca++ uptake to diminish activation of the Ca++-dependent K+ channel; or (3) by retarding K+ efflux (via reduction of anion conductance) through any K+ channels that were activated by residual sickling-induced Ca++ uptake. Whether dipyridamole is capable of inhibiting SS RBC cation loss and dehydration in vivo will depend on several factors. First is the relative involvement of the inhibited pathways in the process of dehydration, compared with KCl cotransport, which is not affected. Brugnara and colleagues10 have shown that clotrimazole, an inhibitor of the Ca++-activated K+ channel, increases SS RBC cation content and reduces the number of dense cells in patients treated orally. This suggests that Ca++-activated K+ channel activation by sickling does indeed contribute to dehydration in vivo. A second factor that will affect the clinical efficacy of dipyridamole in sickle cell patients is the degree of inhibition of the sickling-induced pathways achievable in vivo by oral dosing. The present results suggest that membrane levels of drug sufficient for inhibition of these pathways are found in patients taking moderate therapeutic doses of dipyridamole. Chaplin et al33 conducted a clinical study to determine if dipyridamole combined with aspirin would reduce the frequency and severity of vaso-occlusive episodes and mitigate the associated coagulation abnormalities. They treated 3 patients for several years in a nonblinded, longitudinal crossover study, accruing a total of 340 patient weeks on medication and 315 weeks off drug. Fibrinogen levels were not affected by treatment, although the increases in platelet count and high molecular weight fibrin complexes associated with pain episodes in control periods did not occur during treatment. During the study, there were no signs of toxicity or episodes of excessive bleeding. While on aspirin and dipyridamole, patients had approximately half the number of pain episodes and hospital days compared with control periods, findings remarkably similar to those of the multicenter trial of hydroxyurea in sickle cell disease.34 Hematological parameters were not measured, so no assessment of the effect of dipyridamole/aspirin treatment on RBC hydration state can be made. Although this study is small, it suggests that dipyridamole treatment is safe in sickle cell patients and might result in improvement in vaso-occlusive symptoms. Several pilot studies have been based on reducing SS RBC dehydration by inhibition of various transport pathways. Brugnara and colleagues10 demonstrated that clotrimazole, an inhibitor of the Ca++-activated K+ channel, could block deoxygenation-induced dense cell formation in vitro. Oral administration of clotrimazole to sickle cell patients,35 as well as to transgenic sickle cell mice,36 reduced the number of dense sickle cells in vivo. Following a suggestion first made by Bookchin et al,37 De Franceschi et al38,39 used oral Mg++ to increase cellular Mg++, thereby inhibiting the KCl cotransporter, thought to be an important mediator of cation loss in sickle reticulocytes.4,11 Mg++ supplementation reduced in vivo SS RBC dehydration in both mice and humans.38,39 In combination with other transport inhibitors, the inhibitory activity of dipyridamole against the sickling-induced transport pathway may prove useful in achieving inhibition of sickle cell dehydration in vivo with low levels of toxicity.
The authors wish to thank the many volunteers who donated blood samples to this study; Dr Donald Rucknagel and Annette Lavender, University Hospital of Cincinnati, for their assistance with obtaining these samples; and Mary Palascak and Ben Girdler for technical assistance.
Submitted November 30, 2000; accepted February 23, 2001.
Supported by US Public Health grants P60 HL58421 (C.H.J., R.S.F.), R01 HL57614 (C.H.J.), and R01 HL 51174 (R.S.F.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Clinton H. Joiner, Director, Comprehensive Sickle Cell Center, Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229-3039; e-mail: clint.joiner{at}chmcc.org.
1. Horiuchi K, Onyike AE, Osterhout ML. Sickling in vitro of reticulocytes from patients with sickle cell disease at venous oxygen tension. Exp Hematol. 1998;24:68-76.
2.
Joiner CH, Morris CL, Cooper ES.
Deoxygenation-induced cation fluxes in sickle cells, III: cation selectivity and response to pH and membrane potential.
Am J Physiol.
1993;264:C734-C744
3.
Joiner CH, Jiang M, Franco RS.
Deoxygenation-induced cation fluxes in sickle cells, IV: modulation by external calcium.
Am J Physiol.
1995;269:C403-C409 4. Bookchin RM, Ortiz OE, Lew VL. Evidence for a direct reticulocyte origin of dense red cells in sickle cell anemia. J Clin Invest. 1991;87:113-124.
5.
Ortiz OE, Lew VL, Bookchin RM.
Deoxygenation permeabilizes sickle cell anaemia red cells to magnesium and reverses its gradient in the dense cells.
J Physiol.
1990;427:211-226
6.
Rhoda MD, Apova M, Beuzard Y, Giraud F.
Ca++ permeability in deoxygenated sickle cells.
Blood.
1990;75:2453-2458 7. Etzion Z, Tieffert T, Bookchin RM, Lew VL. Effects on deoxygenation on active and passive Ca2+ transport and on the cytoplasmic Ca2+ levels of sickle cell anemia red cells. J Clin Invest. 1993;2:2489-2498. 8. Lew VL, Ortiz OE, Bookchin RM. Stochastic nature and red cell population distribution of the sickling-induced Ca2+ permeability. J Clin Invest. 1997;99:2727-2735[Medline] [Order article via Infotrieve]. 9. Joiner CH, Platt OS, Lux SE. Cation depletion by the sodium pump in red cells with pathological cation leaks: sickle cells and xerocytes. J Clin Invest. 1986;78:1487-1496. 10. Brugnara C, deFranceschi L, Alper SL. Inhibition of Ca2+-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest. 1993;92:520-526.
11.
Franco RS, Palascak M, Thompson H, Rucknagel DL, Joiner CH.
Dehydration of transferrin receptor-positive sickle reticulocytes during continuous or cyclic deoxygenation: role of KCl cotransport and extracellular calcium.
Blood.
1996;88:4359-4365 12. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990;40:63-279[Medline] [Order article via Infotrieve]. 13. Joiner CH, Gunn RB, Fröhlich O. Anion transport in sickle red blood cells. Pediatr Res. 1990;28:587-590[Medline] [Order article via Infotrieve].
14.
Joiner CH.
Deoxygenation-induced fluxes in sickle cells, II: inhibition by stilbene disulfonates.
Blood.
1990;76:212-220 15. Ohnishi S, Horiuchi KY, Horiuchi K, Jurman ME, Sadanaga KK. Nitrendipine, nifedipine and verapamil inhibit the in vitro formation of irreversibly sickled cells. Pharmacology. 1986;32:248-256[CrossRef][Medline] [Order article via Infotrieve]. 16. Joiner CH, Jiang M. Inhibition of deoxygenation-induced calcium influx in sickle red blood cells by dipyridamole and other transport inhibitors [abstract]. Blood. 1995;86:299a. 17. Joiner CH, Jiang M. Dipyridamole inhibits deoxygenation-induced cation fluxes in sickle cells Rosa J, Beuzard Y, Lubin B, eds, New Trends in Therapies for Hemoglobinopathies and Thalassemias. Paris, France: INSERM/John Libbey; 1995:525-542. 18. Legrum B, Passow H. Inhibition of inorganic anion transport across the human red blood cell membrane by choloride-dependent association of dipyridamole with a stilbene disulfonate binding site on the band 3 protein. Biochim Biophys Acta. 1989;979:193-207[Medline] [Order article via Infotrieve]. 19. Kalsi KK, Smolenski RT, Yacoub MH. Effects of nucleoside transport inhibitors and adenine/ribose supply on ATP concentration and adenosine production in cardiac myocytes. Mol Cell Biochem. 1998;180:193-199[CrossRef][Medline] [Order article via Infotrieve].
20.
Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB.
Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase.
J Biol Chem.
1998;273:15559-15564 21. Szasz I, Sarkadi B, Gardos G. Effect of drugs on the calcium-dependent rapid potassium transport in calcium-loaded intact red cells. Acta Biochim Biophys Acad Sci Hung. 1978;13:133-141[Medline] [Order article via Infotrieve]. 22. Lew VL, Tsien RY, Miner C. Physiological [Ca2+]i level and pump-leak turnover in intact red cells measured using an incorporated Ca chelator. Nature. 1982;298:478-481[CrossRef][Medline] [Order article via Infotrieve].
23.
Lowry OH, Rosebrought NJ, Farr AL, Randall RJ.
Protein measurement with the Folin phenol reagent.
J Biol Chem.
1951;193:265-275 24. Eaton JW, Branda RF, Hoadland C, Dreher K. Anion channel blockade: effects on erythrocyte membrane calcium response. Am J Hematol. 1980;9:391-399[Medline] [Order article via Infotrieve].
25.
Bennekou P, Pedersen O, Moller A, Christophersen P.
Volume control in sickle cells is facilitated by the novel anion conductance inhibitor NS1652.
Blood.
2000;95:1842-1848
26.
Knauf PA, Law FY, Marchant PJ.
Relationship between net chloride flow across the human erythrocyte membrane to the anion exchange mechanism.
J Gen Physiol
1984;81:95-104
27.
Joiner CH, Jiang M, Fathallah H, Giraud F, Franco RS.
Deoxygenation of sickle red blood cells stimulates KCl cotransport without affecting Na/H exchange.
Am J Physiol.
1998;274:C1466-C1475 28. Iuliano L, Colavita AR, Camastra C, et al. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol. 1996;119:1438-1446[Medline] [Order article via Infotrieve]. 29. Johnson RM, Tang K. DIDS inhibition of deformation-induced cation flux in human erythrocytes. Biochim Biophys Acta. 1993;1148:7-14[Medline] [Order article via Infotrieve].
30.
Sugihara T, Yawata Y, Hebbel RP.
Deformation of swollen erythrocytes provides a model of sickling-induced leak pathways, including a novel bromide-sensitive component.
Blood.
1994;83:2684-2691 31. Jiang M, Joiner CH. Non-selective cation channels in sickle membranes spicules are inhibited by DIDS, a stilbene disultonate drug which blocks sickling-induced cation fluxes in intact cells [abstract]. Blood. 1999;94:198a. 32. Bennekou P. The feasibility of pharmacological volume control of sickle cells is dependent on the quantization of the transport pathways: a model study. J Theor Biol. 1999;196:129-137[CrossRef][Medline] [Order article via Infotrieve]. 33. Chaplin H, Alkjaersig N, Fletcher AP, Michael JM, Joinst JH. Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost. 1980;43:218-221[Medline] [Order article via Infotrieve].
34.
Charache S, Terrin ML, Moore RD, et al.
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
New Engl J Med.
1995;332:1317-1322 35. Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest. 1996;97:1227-1234[Medline] [Order article via Infotrieve]. 36. De Franceschi L, Saadane N, Trudel M, Alper SL, Brugnara C, Beuzard Y. Treatment with oral clortimazole blocks Ca++-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice: a model for therapy of sickle cell disease. J Clin Invest. 1994;93:1670-1676. 37. Bookchin RM, Tieffert JT, Davies SC, Vichinsky E, Lew VL. Magnesium therapy for sickle cell anemia: a new rationale. In: Rosa J,Beuzard Y,Lubin B, eds. New Trends in Therapies for Hemoglobinopathies and Thalassemias. Paris, France: INSERM/John Libbey; 1995:555-546.
38.
De Franceschi L, Beuzard Y, Jouault H, Brugnara C.
Modulation of erythrocyte potassium chloride cotransport, potassium, and density by dietary magnesium intake in transgenic SAD mouse.
Blood.
1996;88:2738-2744 39. De Franceschi L, Bachir D, Galacteros F, et al. Oral magniesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest. 1997;100:1847-1852[Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. A. Browning, H. M. Staines, H. C. Robinson, T. Powell, J. C. Ellory, and J. S. Gibson The effect of deoxygenation on whole-cell conductance of red blood cells from healthy individuals and patients with sickle cell disease Blood, March 15, 2007; 109(6): 2622 - 2629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Telen Role of Adhesion Molecules and Vascular Endothelium in the Pathogenesis of Sickle Cell Disease Hematology, January 1, 2007; 2007(1): 84 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Kalfa, S. Pushkaran, N. Mohandas, J. H. Hartwig, V. M. Fowler, J. F. Johnson, C. H. Joiner, D. A. Williams, and Y. Zheng Rac GTPases regulate the morphology and deformability of the erythrocyte cytoskeleton Blood, December 1, 2006; 108(12): 3637 - 3645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Lew and R. M. Bookchin Ion Transport Pathology in the Mechanism of Sickle Cell Dehydration Physiol Rev, January 1, 2005; 85(1): 179 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Holtzclaw, M. Jiang, Z. Yasin, C. H. Joiner, and R. S. Franco Rehydration of high-density sickle erythrocytes in vitro Blood, September 26, 2002; 100(8): 3017 - 3025. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
dehydration 
, Na+ influx; 
,
K+ efflux.
) (B). For both measurements,
deoxygenation was carried out under similar conditions in parallel. Net
Na+ and K+ fluxes were measured in the presence
of 100 µM ouabain. Sickling-induced fluxes were calculated as
described in Figure 
